236 related articles for article (PubMed ID: 31144250)
1. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.
Volpi S; Insalaco A; Caorsi R; Santori E; Messia V; Sacco O; Terheggen-Lagro S; Cardinale F; Scarselli A; Pastorino C; Moneta G; Cangemi G; Passarelli C; Ricci M; Girosi D; Derchi M; Bocca P; Diociaiuti A; El Hachem M; Cancrini C; Tomà P; Granata C; Ravelli A; Candotti F; Picco P; DeBenedetti F; Gattorno M
J Clin Immunol; 2019 Jul; 39(5):476-485. PubMed ID: 31144250
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey.
Balci S; Ekinci RMK; de Jesus AA; Goldbach-Mansky R; Yilmaz M
Clin Immunol; 2020 Mar; 212():108273. PubMed ID: 31626957
[TBL] [Abstract][Full Text] [Related]
3. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype.
Clarke SLN; Robertson L; Rice GI; Seabra L; Hilliard TN; Crow YJ; Ramanan AV
Pediatr Rheumatol Online J; 2020 May; 18(1):37. PubMed ID: 32398023
[TBL] [Abstract][Full Text] [Related]
4. Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome.
Berrada KR; Belot A; Neven B; Ohlmann C; Tronc F; Rice G; Thouvenin G; Dubus JC; Mazenq J; Frémond ML; Stremler N; Soummer-Feuillet S; Cottin V; Reix P
J Clin Immunol; 2023 Nov; 43(8):2156-2164. PubMed ID: 37814086
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
6. Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy.
Wu J; Zhou Q; Zhou H; Lu M
Pediatr Rheumatol Online J; 2023 Oct; 21(1):131. PubMed ID: 37884945
[TBL] [Abstract][Full Text] [Related]
7. [Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China].
Yu ZX; Zhong LQ; Song HM; Wang CY; Wang W; Li J; Ma MS
Zhonghua Er Ke Za Zhi; 2018 Mar; 56(3):179-185. PubMed ID: 29518827
[No Abstract] [Full Text] [Related]
8. STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib.
Tang X; Xu H; Zhou C; Peng Y; Liu H; Liu J; Li H; Yang H; Zhao S
J Clin Immunol; 2020 Jan; 40(1):114-122. PubMed ID: 31705453
[TBL] [Abstract][Full Text] [Related]
9. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
Front Immunol; 2022; 13():825367. PubMed ID: 35418997
[TBL] [Abstract][Full Text] [Related]
10. A Novel Biallelic
Alghamdi MA; Mulla J; Saheb Sharif-Askari N; Guzmán-Vega FJ; Arold ST; Abd-Alwahed M; Alharbi N; Kashour T; Halwani R
Front Immunol; 2020; 11():599564. PubMed ID: 33488593
[TBL] [Abstract][Full Text] [Related]
11. Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients.
Frémond ML; Hadchouel A; Berteloot L; Melki I; Bresson V; Barnabei L; Jeremiah N; Belot A; Bondet V; Brocq O; Chan D; Dagher R; Dubus JC; Duffy D; Feuillet-Soummer S; Fusaro M; Gattorno M; Insalaco A; Jeziorski E; Kitabayashi N; Lopez-Corbeto M; Mazingue F; Morren MA; Rice GI; Rivière JG; Seabra L; Sirvente J; Soler-Palacin P; Stremler-Le Bel N; Thouvenin G; Thumerelle C; Van Aerde E; Volpi S; Willcocks S; Wouters C; Breton S; Molina T; Bader-Meunier B; Moshous D; Fischer A; Blanche S; Rieux-Laucat F; Crow YJ; Neven B
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):803-818.e11. PubMed ID: 33217613
[TBL] [Abstract][Full Text] [Related]
12. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
13. Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).
David C; Frémond ML
Cells; 2022 Jan; 11(3):. PubMed ID: 35159128
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Acute Thrombotic Microangiopathy in a Patient with STING-Associated Vasculopathy with Onset in Infancy (SAVI).
Ma M; Mazumder S; Kwak H; Adams M; Gregory M
J Clin Immunol; 2020 Nov; 40(8):1111-1115. PubMed ID: 32860170
[TBL] [Abstract][Full Text] [Related]
15. A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report.
Weidler S; Koss S; Wolf C; Lucas N; Brunner J; Lee-Kirsch MA
Pediatr Rheumatol Online J; 2024 Jan; 22(1):9. PubMed ID: 38178067
[TBL] [Abstract][Full Text] [Related]
16. STING-associated vasculopathy with onset in infancy: a familial case series report and literature review.
Wang Y; Wang F; Zhang X
Ann Transl Med; 2021 Jan; 9(2):176. PubMed ID: 33569478
[TBL] [Abstract][Full Text] [Related]
17. The Challenge of Diagnosing SAVI: Case Studies.
Cao Y; Jiang LP
Pediatr Allergy Immunol Pulmonol; 2019 Dec; 32(4):167-172. PubMed ID: 32140288
[No Abstract] [Full Text] [Related]
18. STING-associated vasculopathy with onset in infancy (SAVI) presenting with skin lesions.
Latour-Álvarez I; Murcia-Clemente L; Vázquez-Pigueras I; Garramone-Ramírez JE; Clemente D; Sanz V; Torrelo A
Pediatr Dermatol; 2024 Apr; ():. PubMed ID: 38682895
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
20. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
